• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is AbbVie’s (ABBV) SKYRIZI Push and Apogee Deal Reframing Its Immunology-Centered Investment Story?

    Simply Wall St·08/20/2026 16:26:30
    語音播報
    • In recent weeks, AbbVie has highlighted the pending review of a subcutaneous induction option for SKYRIZI in Crohn’s disease, continued portfolio expansion through deals such as its roughly US$10.90 billion Apogee Therapeutics acquisition, and the ongoing recognition of its long-running immunology scholarship program.
    • Together, these developments underscore how heavily AbbVie’s outlook is tied to SKYRIZI’s future use, while it simultaneously invests in new therapies and reinforces its image as a patient-focused, dividend-paying large-cap biopharma group.
    • We’ll now examine how the anticipated SKYRIZI dosing change could influence AbbVie’s investment narrative built around immunology-driven growth.

    AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    AbbVie Investment Narrative Recap

    To own AbbVie, you need to be comfortable with a large share of its revenue coming from a single immunology drug, SKYRIZI, while accepting regulatory, pricing and concentration risks. The pending review of a subcutaneous induction option for SKYRIZI in Crohn’s disease is currently the key short term catalyst, and the recent updates mainly reinforce how dependent AbbVie’s near term story is on this one medicine.

    Among recent announcements, AbbVie’s roughly US$10.90 billion Apogee Therapeutics acquisition stands out because it extends the immunology portfolio beyond SKYRIZI. For investors, that matters in the context of today’s catalysts, as it slightly broadens future revenue sources while SKYRIZI remains at the center of AbbVie’s growth narrative and risk profile.

    Yet investors should also recognize how heavily concentrated AbbVie’s revenue is in SKYRIZI, especially if...

    Read the full narrative on AbbVie (it's free!)

    AbbVie's narrative projects $81.5 billion revenue and $24.6 billion earnings by 2029. This requires 8.2% yearly revenue growth and a roughly $18.3 billion earnings increase from $6.3 billion today.

    Uncover how AbbVie's forecasts yield a $273.39 fair value, a 3% upside to its current price.

    Exploring Other Perspectives

    ABBV 1-Year Stock Price Chart
    ABBV 1-Year Stock Price Chart

    Three Simply Wall St Community fair value estimates span roughly US$273 to US$457 per share, underlining how far apart individual views can be. When you weigh these against AbbVie’s heavy reliance on SKYRIZI for a large share of revenue, it becomes even more important to compare several perspectives on what could shape the company’s performance over time.

    Explore 3 other fair value estimates on AbbVie - why the stock might be worth as much as 72% more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Looking For Alternative Opportunities?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.